GREM1 可能是膀胱癌的生物学标志物和潜在靶点。
GREM1 may be a biological indicator and potential target of bladder cancer.
机构信息
Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, 315211, Zhejiang, China.
Department of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, 317000, Zhejiang, China.
出版信息
Sci Rep. 2024 Oct 7;14(1):23280. doi: 10.1038/s41598-024-73655-7.
Gremlin 1 (GREM1) can regulate the development of many cancers. However, a few studies have revealed the role of GREM1 in bladder cancer (BC). To evaluate the expression and potential function of GREM1 in bladder cancer, we used R version 3.6.3 and related packages to analyze the data from common databases. Samples from our institution were assessed by immunohistochemical staining (IHC), which was approved by the Institutional Ethics Committee (K20220830). GREM1 was highly expressed in BC tissues according to the TCGA and IHC data. Data from TCGA, GSE31684, GSE32894, and IHC showed that GREM1 has significant prognostic value for BC patients. GREM1 is involved in immune and metabolism-related pathways. According to the TIDE algorithm, 61.0% of patients with low GREM1 expression responded well to immunotherapy, compared to only 13.3% in the high GREM1 expression group. High GREM1 expression was associated with sensitivity to cisplatin, docetaxel, gemcitabine, and vinblastine. Thus, GREM1 can predict prognosis and responses to immunotherapy and chemotherapy in BC patients, making it a potential biomarker and therapeutic target.
GREM1（Gremlin 1）可以调节多种癌症的发展。然而，少数研究揭示了 GREM1 在膀胱癌（BC）中的作用。为了评估 GREM1 在膀胱癌中的表达和潜在功能，我们使用 R 版本 3.6.3 和相关软件包分析了来自公共数据库的数据。我们机构的样本通过免疫组织化学染色（IHC）进行评估，该研究得到了机构伦理委员会的批准（K20220830）。根据 TCGA 和 IHC 数据，GREM1 在 BC 组织中高表达。来自 TCGA、GSE31684、GSE32894 和 IHC 的数据表明，GREM1 对 BC 患者具有显著的预后价值。GREM1 参与免疫和代谢相关途径。根据 TIDE 算法，低表达 GREM1 的患者中有 61.0%对免疫治疗反应良好，而高表达 GREM1 的患者中仅有 13.3%。高 GREM1 表达与顺铂、多西他赛、吉西他滨和长春碱的敏感性相关。因此，GREM1 可以预测 BC 患者的预后和对免疫治疗和化疗的反应，使其成为有潜力的生物标志物和治疗靶点。
Zotero 插件